For instance, in a clinical study that used cord blood-derived NK cells to manufacture CAR-NK cells for the treatment of relapsed or refractory CD19+ lymphoid tumors, none of the 11 participants developed inflammatory toxicities such as CRS or ICANS (11). This evidence concerns the gene CD19 and congenital rubella syndrome.